One-year outcomes after water vapor thermal therapy for symptomatic benign prostatic hyperplasia in an unselected Italian multicenter cohort.


Journal

Minerva urology and nephrology
ISSN: 2724-6442
Titre abrégé: Minerva Urol Nephrol
Pays: Italy
ID NLM: 101777299

Informations de publication

Date de publication:
Apr 2023
Historique:
medline: 3 4 2023
pubmed: 20 1 2023
entrez: 19 1 2023
Statut: ppublish

Résumé

Water vapor therapy (Rezum Patients with BPO and moderate to severe LUTS who underwent Rezum Overall, 352 patients were eligible for the analysis. Procedures were routinely done on an outpatient basis. Mean operative was 12 minutes. The catheter was left in place for a median of 7 days. After treatment, Q<inf>max</inf>, IPSS and IPSS-QoL, OAB-q SF, ICIQ-UI SF and IIEF-5 from baseline to last control follow-up (median 16, IQR 13-20 months) were improved (P<0.05). The postoperative anterograde ejaculation rate was recorded in 74.1% vs. preoperative 43.8% (P<0.001). Early (≤30 days) postoperative complications occurred in 176 patients (50%), all Clavien-Dindo Grade ≤2. One patient experienced clot retention and hematuria requiring hospitalization and blood transfusion. No late AEs were recorded. Surgical retreatment rate was 2.5% (9/352), all cases occurred within the first year. Median PGI-I was 2 (1-2). We confirmed the safety and efficacy of water vapor therapy for the treatment of symptomatic benign prostatic obstruction (BPO) on a large cohort of patients. Anterograde ejaculation was preserved in the majority of patients, with good subjective improvement. Further studies may rule out possible role of Rezum

Sections du résumé

BACKGROUND BACKGROUND
Water vapor therapy (Rezum
METHODS METHODS
Patients with BPO and moderate to severe LUTS who underwent Rezum
RESULTS RESULTS
Overall, 352 patients were eligible for the analysis. Procedures were routinely done on an outpatient basis. Mean operative was 12 minutes. The catheter was left in place for a median of 7 days. After treatment, Q<inf>max</inf>, IPSS and IPSS-QoL, OAB-q SF, ICIQ-UI SF and IIEF-5 from baseline to last control follow-up (median 16, IQR 13-20 months) were improved (P<0.05). The postoperative anterograde ejaculation rate was recorded in 74.1% vs. preoperative 43.8% (P<0.001). Early (≤30 days) postoperative complications occurred in 176 patients (50%), all Clavien-Dindo Grade ≤2. One patient experienced clot retention and hematuria requiring hospitalization and blood transfusion. No late AEs were recorded. Surgical retreatment rate was 2.5% (9/352), all cases occurred within the first year. Median PGI-I was 2 (1-2).
CONCLUSIONS CONCLUSIONS
We confirmed the safety and efficacy of water vapor therapy for the treatment of symptomatic benign prostatic obstruction (BPO) on a large cohort of patients. Anterograde ejaculation was preserved in the majority of patients, with good subjective improvement. Further studies may rule out possible role of Rezum

Identifiants

pubmed: 36656128
pii: S2724-6051.22.05080-7
doi: 10.23736/S2724-6051.22.05080-7
doi:

Substances chimiques

Steam 0

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

203-209

Auteurs

Luca Cindolo (L)

Department of Urology, Villa Stuart Private Hospital, Rome, Italy.
Department of Urology, Hesperia Hospital, Modena, Italy.

Simone Morselli (S)

Department of Urology, Hesperia Hospital, Modena, Italy - simone.morselli@unifi.it.
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Davide Campobasso (D)

Department of Urology, University Hospital of Parma, Parma, Italy.

Enrico Conti (E)

Department of Urology, Levante Ligure Hospital, La Spezia, Italy.

Giancarlo Sebastiani (G)

Department of Urology, Levante Ligure Hospital, La Spezia, Italy.

Francesco Franzoso (F)

Department of Urology, Hospital of Desio, Desio, Monza-Brianza, Italy.

Giuseppe Galluccio (G)

Department of Urology, Hospital of Desio, Desio, Monza-Brianza, Italy.

Daniele Maruzzi (D)

Department of Urology, Santa Maria Degli Angeli Hospital, Pordenone, Italy.

Francesco Visalli (F)

Department of Urology, Santa Maria Degli Angeli Hospital, Pordenone, Italy.

Francesco Varvello (F)

Department of Urology, Michele e Pietro Ferrero Hospital, Alba, Cuneo, Italy.

Marco Lucci Chiarissi (M)

Department of Urology, Michele e Pietro Ferrero Hospital, Alba, Cuneo, Italy.

Lorenzo Viola (L)

Department of Urology, San Luca Nuovo, Careggi Hospital, University of Florence, Florence, Italy.

Francesco Sessa (F)

Department of Urology, San Luca Nuovo, Careggi Hospital, University of Florence, Florence, Italy.

Stefano Toso (S)

Department of Urology, Hesperia Hospital, Modena, Italy.
Department of Urology, University of Modena and Reggio Emilia, Modena, Italy.

Salvatore Micali (S)

Department of Urology, University of Modena and Reggio Emilia, Modena, Italy.

Giovanni Ferrari (G)

Department of Urology, Hesperia Hospital, Modena, Italy.

Giampaolo Siena (G)

Department of Urology, San Luca Nuovo, Careggi Hospital, University of Florence, Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH